239 related articles for article (PubMed ID: 28329281)
1. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
[TBL] [Abstract][Full Text] [Related]
2. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
3. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
[TBL] [Abstract][Full Text] [Related]
4. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
6. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.
Eschenauer GA; Carver PL; Lin SW; Klinker KP; Chen YC; Potoski BA; Shields RK; Clancy CJ; Nguyen MH; Lam SW
J Antimicrob Chemother; 2013 Apr; 68(4):922-6. PubMed ID: 23212115
[TBL] [Abstract][Full Text] [Related]
9. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis.
Fernández-Ruiz M; Aguado JM; Almirante B; Lora-Pablos D; Padilla B; Puig-Asensio M; Montejo M; García-Rodríguez J; Pemán J; Ruiz Pérez de Pipaón M; Cuenca-Estrella M; ; ;
Clin Infect Dis; 2014 May; 58(10):1413-21. PubMed ID: 24642553
[TBL] [Abstract][Full Text] [Related]
10. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
11. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort.
López-Cortés LE; Almirante B; Cuenca-Estrella M; Garnacho-Montero J; Padilla B; Puig-Asensio M; Ruiz-Camps I; Rodríguez-Baño J;
Clin Microbiol Infect; 2016 Aug; 22(8):733.e1-8. PubMed ID: 27189197
[TBL] [Abstract][Full Text] [Related]
12. Impact of biofilm production by Candida species and antifungal therapy on mortality of patients with candidemia.
Lee CH; Chen YC; Chen IL; Chen FJ; Chien CC
Mycoses; 2020 Dec; 63(12):1382-1391. PubMed ID: 32910518
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
Bienvenu AL; Pradat P; Guerin C; Aubrun F; Fellahi JL; Friggeri A; Guichon C; Hernu R; Menotti J; Monard C; Paulus S; Rimmele T; Piriou V; Chidiac C; Argaud L; Leboucher G
Int J Infect Dis; 2020 Apr; 93():15-21. PubMed ID: 31982622
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.
Lin KY; Chen PY; Chuang YC; Wang JT; Sun HY; Sheng WH; Chen YC; Chang SC
J Infect; 2018 Sep; 77(3):242-248. PubMed ID: 29932963
[TBL] [Abstract][Full Text] [Related]
15. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Coste AT; Kritikos A; Li J; Khanna N; Goldenberger D; Garzoni C; Zehnder C; Boggian K; Neofytos D; Riat A; Bachmann D; Sanglard D; Lamoth F;
Infection; 2020 Oct; 48(5):761-766. PubMed ID: 32661647
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
18. Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome.
Fernández-Ruiz M; Cardozo C; Salavert M; Aguilar-Guisado M; Escolà-Vergé L; Muñoz P; Gioia F; Montejo M; Merino P; Cuervo G; García-Vidal C; Aguado JM; ;
Transpl Infect Dis; 2019 Dec; 21(6):e13195. PubMed ID: 31610077
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
20. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
